Autolus Therapeutics PLC
NASDAQ:AUTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
UK |
|
Arhaus Inc
NASDAQ:ARHS
|
US |
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
IL |
|
Companhia Estadual de Distribuicao de Energia Eletrica CEEED
BOVESPA:CEED4
|
BR |
|
R
|
Royal Unibrew A/S
OTC:ROYUF
|
DK |
|
Hunan Sundy Science and Technology Co Ltd
SZSE:300515
|
CN |
Autolus Therapeutics PLC
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
Launch momentum: Autolus said AUCATZYL had a very good first year in the U.S., with $74.3 million in 2025 revenue and 67 activated centers by year-end.
2026 outlook: Management reiterated full-year 2026 revenue guidance of $120 million to $135 million, expects positive gross margins in 2026, and aims to expand to more than 80 activated centers.
Real-world data: The ROCCA consortium data suggested AUCATZYL’s safety and early response rates in practice were in line with the earlier FELIX study, including no Grade 3+ CRS in the real-world dataset.
Pipeline breadth: Autolus highlighted progress in pediatric ALL, lupus nephritis, and progressive MS, with multiple data readouts expected from 2026 through 2028.
Cash runway: The company ended 2025 with $300.7 million in cash, cash equivalents, and marketable securities and said that is enough to fund operations into Q4 2027.
